ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study

Xiao, Zhiwei; Sun, Lingling; Zheng, Yating; Chen, Hanrui; Zheng, Xinting; Luo, Jiamin; Gu, Chuying; Lin, Ruiting; Huang, Mengli; Bai, Yuezong; Chen, Zhe-Sheng; Kinslow, Connor J.; Loh, Jerold; Lin, Lizhu*广州中医药大学; 1
Translational Lung Cancer Research2022-12DOI: 10.21037/tlcr-22-746
20阅读
引用收藏
分享

摘要

Background: Platinum-based chemotherapy (PC) and immunotherapy plus platinum-based chemotherapy (IPC) remain the first-line treatment for advanced NSCLC. But only a minority patients benefit from PC, and existing biomarkers, such as PD-L1, have been shown to be defective in predicting the efficacy of IPC. Highlighting the need to identify novel biomarkers for the efficacy of PC and IPC. DNA damage repair (DDR) mutations are known to predict response to PC in solid tumors. However, the predictive value of DDR in PC and IPC of NSCLC remains unclear.Methods: Patients diagnosed with advanced or metastatic NSCLC were retrospectively included if they underwent next generation sequencing prior to starting treatment. Primary endpoints were to explore whether DDR mutations (DDRmut) are associated with clinical outcomes of PC and IPC. Secondary end point were to explore the association between DDRmut and the choice to add immunotherapy to chemotherapy, and the impact of different DDR pathways on efficacy in PC and IPC.Results: DDRmut showed a strong association with tumor mutation burden-high (TMB-H) versus DDR wild-type (DDRwt) and higher rates of PD-L1 TPS >= 50% positivity. In 63 patients treated with PC, ORRs were 15.38% and 2.86% for DDRmut and DDRwt subgroup (P=0.1536), and DCRs were 88.46% and 45.72% (P=0.00097) at 6 months after PC. The DDRmut patients had significantly improved median PFS (mPFS) and median overall survival (mOS) than DDRwt group (mPFS: 7.6 vs. 3.9 months, HR =1.93, 95% CI: 1.09 to 3.14, P=0.0220. mOS: 29.9 vs. 20.7 months, HR =2.31, 95% CI: 1.09 to 4.9, P=0.0250). Moreover, among 37 patients treated with IPC, ORRs were 45% and 11.76% for DDRmut and DDRwt patients (P=0.0365), and the DCRs were 95% and 70.58% (P=0.0752), respectively at 6 months after IPC. The DDRmut patients had significantly improved mPFS compared to the DDRwt group (19.5 vs. 4.5 months, HR =3.28, 95% CI: 1.53 to 9.56, P=0.0022). In DDRmut group, mPFS of IPC recipients was significantly better than that of PC recipients (19.5 vs. 7.6 months, HR =2.09, 95% CI: 0.98 to 4.42, P=0.050).Conclusions: There is potential for DDR to serve as a positive predictor of PC and IPC in advanced NSCLC patients.

学科与关键词

关键词
Non-small cell lung cancer (NSCLC)platinum-based chemotherapy (PC)immunotherapy plus platinum-based chemotherapy (IPC)DNA damage repair (DDR)prediction
相关
加载中…
  • DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients
    Gu, Weiguang*; Zhuang, Wenya; Zhuang, Mengxia; He, Minhong; Li, ZhihuaDiagnostic Pathology, 2023, 18(1): 119.
  • DNA damage repair gene mutations predict the efficacy of immunization combined with platinum chemotherapy in advanced non-small cell lung cancer: A retrospective cohort study
    Xiao, Zhiwe; Sun, Lingling; Zheng, Yating; Chen, Hanrui; Zheng, Xinting; Luo, Jiamin; Gu, Chuying; Lin, Ruiting; Hu, Xue; Huang, Mengli; Lin, LizhuAnnual Meeting of the American-Association-for-Cancer-Research (AACR), New Orleans, LA, 2022-04-08 To 2022-04-13.
  • DNA damage repair gene mutations predict the efficacy of immunization combined with platinum chemotherapy in advanced non-small cell lung cancer: A retrospective cohort study.
    Xiao, Zhiwe; Sun, Lingling; Zheng, Yating; Chen, Hanrui; Zheng, Xinting; Luo, Jiamin; Gu, Chuying; Lin, Ruiting; Hu, Xue; Huang, Mengli; Lin, LizhuAnnual Meeting of the American-Association-for-Cancer-Research (AACR), New Orleans, LA, 2022-04-08 To 2022-04-13.
查看全部 →

发表信息

论文状态
公开发表
期刊
Translational Lung Cancer Research
发表日期
2022-12
卷期
第 11 卷, 第 12 期
页码
2539-U159
DOI
10.21037/tlcr-22-746
期刊等级
2区
成果收录
SCIE
资助标注
AME Lung Cancer Collaborative Group

作者

  • X

    Xiao, Zhiwei (第一作者)

    1 · guangzhou univ chinese med

  • S

    Sun, Lingling

    1 · guangzhou univ chinese med

查看全部 14 位作者收起作者
  • Z

    Zheng, Yating

  • C

    Chen, Hanrui

    1 · guangzhou univ chinese med

  • Z

    Zheng, Xinting

    1 · guangzhou univ chinese med

  • L

    Luo, Jiamin

    1 · guangzhou univ chinese med

  • G

    Gu, Chuying

    1 · guangzhou univ chinese med

  • L

    Lin, Ruiting

    1 · guangzhou univ chinese med

  • H

    Huang, Mengli

  • B

    Bai, Yuezong

  • C

    Chen, Zhe-Sheng

  • K

    Kinslow, Connor J.

    new

  • L

    Loh, Jerold

  • L

    Lin, Lizhu (通讯)

    1 · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417